Syneos Health, a leading global biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has rapidly established itself within the research and development services industry, specifically focusing on clinical development and commercialisation.
Syneos Health offers a unique integrated approach, combining clinical and commercial expertise to accelerate the delivery of innovative therapies. Their core services include clinical trial management, regulatory consulting, and market access strategies, all designed to enhance the efficiency of drug development. With a strong market position, Syneos Health has achieved notable milestones, including recognition for its commitment to patient-centric solutions and operational excellence in the biopharmaceutical sector.
+24 vs industry average
Syneos Health’s score of 53 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Syneos Health?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Syneos Health's reported carbon emissions
Syneos Health, a US-based company in the Research and development services (73) industry, is committed to reducing its climate impact. In 2024, the company reported total absolute emissions of approximately 277.8 million kg CO2e. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. Breakdown for 2024: * **Scope 1:** Approximately 16.5 million kg CO2e * **Scope 2 (Market-based):** Approximately 5.1 million kg CO2e * **Scope 3:** Substantial emissions were recorded in Scope 3, with purchased goods and services contributing approximately 172.5 million kg CO2e and business travel accounting for approximately 36.9 million kg CO2e. Employee commute was approximately 5.4 million kg CO2e, capital goods approximately 3.1 million kg CO2e, waste generated in operations approximately 1.9 million kg CO2e, and fuel and energy-related activities approximately 5.3 million kg CO2e. In 2023, Syneos Health's total absolute emissions were approximately 240.7 million kg CO2e. * **Scope 1:** Approximately 16.3 million kg CO2e * **Scope 2 (Market-based):** Approximately 9.7 million kg CO2e * **Scope 3:** Purchased goods and services were approximately 196.2 million kg CO2e, and business travel was approximately 50.7 million kg CO2e. Employee commute was approximately 5.8 million kg CO2e, fuel and energy-related activities approximately 5.3 million kg CO2e, waste generated in operations approximately 1.8 million kg CO2e, and capital goods approximately 1.9 million kg CO2e. **Climate Commitments and Reduction Targets:** Syneos Health has set ambitious targets to address its environmental footprint. The company has joined The Climate Pledge, committing to achieve net zero carbon emissions by 2040. Specific reduction targets aligned with Science Based Targets initiative (SBTi) include: * A commitment to reduce absolute Scope 1 GHG emissions by 42.0% by 2030, using a 2023 base year. * A commitment to reduce absolute Scope 2 GHG emissions by 42.0% by 2030, also from a 2023 base year. * A commitment to reduce absolute Scope 3 GHG emissions from purchased goods and services and business travel by 25.0% by 2030, from a 2023 base year. Additionally, Syneos Health previously set a target to reduce Scope 1 and 2 emissions by 10% and overall emissions by 5% before 2026, compared to a 2021 baseline. The company's reporting indicates that it is on track for this near-term target concerning Scope 3 emissions (purchased goods and services and business travel), as well as Scope 2 emissions.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Syneos Health’s Climate Goals (2030 & 2050)
2 goals2026
5% reduction in all scopes
We set a target to reduce scope 1 and 2 emissions by 10% and overall emissions by 5% before 2026.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
6 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Syneos Health
Frequently asked questions
Common questions about Syneos Health’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project